Clinician Perspectives on Current Issues in Lung Cancer Drug Development
Saiama N. Waqar1, Philip D. Bonomi2, Ramaswamy Govindan1, Fred R. Hirsch3, Gregory J. Riely4, Vassiliki Papadimitrakopoulou5, Dickran Kazandjian6, Sean Khozin6, Erin Larkins6, Dane J. Dickson7, Shakun Malik8, Leora Horn9, Andrea Ferris10, Alice T. Shaw11, Pasi A. Jänne12, Tony S.K. Mok13, Roy Herbst14, Patricia Keegan6, Richard Pazdur6, Gideon M. Blumenthal6
1Division of Oncology, Washington University School of Medicine, St. Louis, Missouri
2Rush University Medical Center, Chicago, Illinois
3University of Colorado Cancer Center, Denver, Colorado.
4Memorial Sloan Kettering Cancer Center, New York, New York
5The University of Texas M. D. Anderson Cancer Center, Houston, Texas
6U.S. Food and Drug Administration, Silver Spring, Maryland
7Oregon Health and Science University, Portland, Oregon
8National Cancer Institute, Bethesda, Maryland;
9Vanderbilt University Medical Center, Nashville, Tennessee
10LUNGevity Foundation, Bethesda, Maryland
11Massachusetts General Hospital Cancer Center, Boston, Massachusetts
12Dana Farber Cancer Institute, Boston, Massachusetts
13The Chinese University of Hong Kong, Hong Kong, People’s Republic of China
14Yale School of Medicine, New Haven, Connecticut
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Journal of Thoracic Oncology
Tập 11
1387-1396
Thông tin tác giả